Company Report
Last edited 6 months ago
PerformanceCommunity EngagementCommunity Endorsement
ranked
#28
Performance (41m)
22.6% pa
Followed by
32
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#ASX Announcements
Added 6 months ago

CORIS® Technology Outperforms Manual Cleaning in Biofilm Removal in Endoscopes

Nanosonics (ASX: NAN), a leader in infection prevention solutions, today announced a new study demonstrating that its CORIS technology outperforms manual cleaning in biofilm removal in endoscopes. The study has been accepted for publication in the Journal of Hospital Infection. https://www.sciencedirect.com/science/article/pii/S0195670124001993.

Despite current cleaning and disinfection efforts, flexible endoscopes can remain long-term reservoirs for infectious organisms. Studies have demonstrated that flexible endoscopes are linked to more patient infections than any other reusable medical device. Biofilm contributes significantly to bacterial persistence in endoscope channels. This can lead to the same strain of bacteria being transmitted to multiple patients from contaminated endoscopes over time.

Co-author of the publication, Dr. Michelle Alfa, a world leading expert on biofilm in endoscopes, commented that "these results showing biofilm removal by the CORIS device are significant given the challenges with biofilm in endoscope reprocessing. In particular, the device removed cyclic build up biofilm from the small diameter channels, while the current manual cleaning approach was not effective. New technologies are required to address this significant problem and CORIS represents an opportunity to improve endoscope reprocessing and help prevent endoscope associated infections."

'The CORIS technology represents a significant opportunity to improve patient safety by addressing what is one of the most significant issues in medical device reprocessing today - the reprocessing of flexible endoscopes. The De Novo regulatory submission to the FDA is currently undergoing review", said Michael Kavanagh, CEO & President.

Michael Kavanagh

CEO / President

#ASX Announcements
stale
Added 2 years ago

Nanosonics (ASX: NAN), today announced the resignation of Chief Financial Officer and Company Secretary, McGregor Grant after 12 years in the role. Mr. Grant will continue as CFO until August 2023.

Michael Kavanagh, CEO and Managing Director, said “McGregor has been an integral part of the Nanosonics Executive team playing a critical role in making Nanosonics a leading Australian global medical device business. During this time, he built our global finance function and capability and has been involved in every aspect of the Nanosonics growth story. McGregor has made a significant and lasting contribution to the success of Nanosonics and together with the Board I sincerely thank McGregor for his valuable service and wish him well in the future.”

Nanosonics has commenced a process to identify a successor for the CFO role.

Mr Matthew Carbines, General Counsel, and member of the Executive team has been appointed as Company Secretary effectively immediately.

Michael Kavanagh

CEO / PresidenT